Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics

Jan. 9, 2012 - PRLog -- GlobalData’s analysis shows that the global Atherosclerosis or Coronary Artery Disease (CAD) therapeutics market stood at $12.0 billion in 2005 and grew at a Compound Annual Growth Rate (CAGR) of 3.8% to reach $14.5 billion in 2010. GlobalData forecasts that the global CAD therapeutics market will grow at a CAGR of 2.1% over the next eight years to reach $17.1 billion by 2018. The current CAD therapeutics market consists of drugs from various therapeutic classes such as statins, Angiotensin- Converting Enzyme (ACE) inhibitors, Beta Blockers (BBs), antiplatelets, Calcium Channel Blockers (CCBs) and nitrates. The current treatment options for CAD mainly include drugs such as Lipitor (atorvastatin calcium), Crestor (rosuvastatin calcium), Angiomax (bivalirudin), Plavix (clopidogrel bisulfate), Norvasc (amlodipine) and Altace (ramipril). The market is expected to show slow growth primarily due to the genericization of key market drugs during the forecast period, which will off-set the effects of the growing prevalence of the disease for the CAD therapeutics market. An increase in the prevalence of CAD is expected in the forecast period, mainly due to increasingly sedentary lifestyles, obesity, hypertension, dyslipidemia, reduction in High Density Lipoprotein Cholesterol (HDL-C) and a high cholesterol diet. The market is set to witness the patent expiration of various drugs, such as Plavix, which went off patent in the EU in 2009 and will lose its US patent in 2012. Lipitor lost its patent in November 2011 in the US and will lose it in 2012 in the EU. Angiomax is set to lose its patent in 2010 in the US and 2015 in the EU. Crestor will lose its patent in 2016 in the US and the EU. These patent expiries will have an impact on the CAD therapeutics market during the forecast period and patients will have access to treatment for CAD at lower prices, reflecting brand erosion of these drugs. However, the expected launch of novel first-in-class (FIC) molecules present in the late stage pipeline and the growing prevalence of the disease will drive the CAD therapeutics market in the coming years.

GlobalData found that the current competition in the CAD therapeutics market is strong due to the availability of a wide range of treatment options. The current CAD therapeutics market is well served, with drugs from various therapeutics classes such as statins, CCBs, BBs and nitrates. These drugs are cost effective and most widely prescribed in combination with ACE inhibitors. The presence of other combination products in the market, coupled with the effect of the impending genericization detailed above, will set the scene for a market share war until the launch of new products with high efficacy and safety profiles.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages....

GlobalData’s research indicates that the CAD pipeline is strong, with 76 molecules in various phases of clinical development. Out of these molecules, 18 are present in Phase III of clinical development process.
Most of the molecules in the pipeline are classified as FIC. Out of 76 molecules present in the pipeline, 53 molecules are First-In-Class (FIC), eight are me-too molecules and four are product extensions in various phases of clinical development. Out of 18 molecules present in phase III, the FIC molecules are Anacetrapib, Dalcetrapib, Darapladib, Vorapaxar, Aliskiren, Mipomersen, Generx, Otamixaban and Varespladib. The strong CAD therapeutics pipeline indicates that in the future, the CAD therapeutics market will witness the launch of various molecules with novel disease-modifying modes of action.
GlobalData, the industry analysis specialist, has released its new report, “Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics market. The report identifies the key trends shaping and driving the global Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Athe...

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com
           
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a global market intelligence services company providing information research and analysis products and services.